Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice: a randomised real-life study

M. R. Sears, L. P. Boulet, M. Laviolette, J. M. FitzGerald, T. R. Bai, N. Smiljanic-Georgijev, J. S. M. Lee (Hamilton, Quebec, Vancouver, Mississauga, Canada)

Source: Annual Congress 2006 - Respiratory diseases in primary care
Session: Respiratory diseases in primary care
Session type: Electronic Poster Discussion
Number: 3601
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. R. Sears, L. P. Boulet, M. Laviolette, J. M. FitzGerald, T. R. Bai, N. Smiljanic-Georgijev, J. S. M. Lee (Hamilton, Quebec, Vancouver, Mississauga, Canada). Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice: a randomised real-life study. Eur Respir J 2006; 28: Suppl. 50, 3601

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 616s
Year: 2007

Budesonide/formoterol maintenance and reliever therapy for asthma in general practice: is it cost-effective?
Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care
Year: 2008

Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double-blind study
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007


Total costs according to reliever use of formoterol turbuhaler in asthma: results from the RELIEF worldwide randomized effectiveness study, stratified by maintenance medication levels
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Budesonide/formoterol adjustable maintenance dosing effectively improves asthma symptom severity: a multicentre Canadian study
Source: Eur Respir J 2003; 22: Suppl. 45, 258s
Year: 2003

Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Budesonide/formoterol maintenance and reliever therapy compared with conventional best standard treatment
Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care
Year: 2008

Overall asthma control with budesonide/formoterol maintenance and relief vs conventional best practice
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008

Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

An electronic patient decision aid comparing as-needed budesonide-formoterol combination to regular use of inhaled corticosteroid (ICS) in mild asthma: a rapid-cycle design study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021


Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma
Source: Eur Respir J 2016; 47: 981-984
Year: 2016


Budesonide/formoterol for maintenance and reliever therapy in real-life in Thailand
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010


Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013


Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020

Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020




Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients
Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Year: 2018




Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma
Source: Eur Respir J, 51 (1) 1701688; 10.1183/13993003.01688-2017
Year: 2018



The Children's Anti-inflammatory Reliever (CARE) study: a protocol for a randomised controlled trial of budesonide-formoterol as sole reliever therapy in children with mild asthma
Source: ERJ Open Res, 7 (4) 00271-2021; 10.1183/23120541.00271-2021
Year: 2021